• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增强型抗体验证,适用于研究应用。

Enhanced validation of antibodies for research applications.

机构信息

Science for Life Laboratory, KTH - Royal Institute of Technology, SE-171 21, Stockholm, Sweden.

Department of Protein Science, KTH - Royal Institute of Technology, SE-106 91, Stockholm, Sweden.

出版信息

Nat Commun. 2018 Oct 8;9(1):4130. doi: 10.1038/s41467-018-06642-y.

DOI:10.1038/s41467-018-06642-y
PMID:30297845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6175901/
Abstract

There is a need for standardized validation methods for antibody specificity and selectivity. Recently, five alternative validation pillars were proposed to explore the specificity of research antibodies using methods with no need for prior knowledge about the protein target. Here, we show that these principles can be used in a streamlined manner for enhanced validation of research antibodies in Western blot applications. More than 6,000 antibodies were validated with at least one of these strategies involving orthogonal methods, genetic knockdown, recombinant expression, independent antibodies, and capture mass spectrometry analysis. The results show a path forward for efforts to validate antibodies in an application-specific manner suitable for both providers and users.

摘要

需要标准化的抗体特异性和选择性验证方法。最近,提出了五种替代验证支柱,使用无需事先了解蛋白质靶标的方法来探索研究抗体的特异性。在这里,我们表明,这些原则可以以简化的方式用于增强 Western blot 应用中研究抗体的验证。使用涉及正交方法、基因敲低、重组表达、独立抗体和捕获质谱分析的这些策略中的至少一种,对 6000 多种抗体进行了验证。结果表明,朝着以适合提供者和用户的特定于应用的方式验证抗体的努力迈进了一步。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/d5f870ec8689/41467_2018_6642_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/12ebcc6ad119/41467_2018_6642_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/7a8ba105042f/41467_2018_6642_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/36c5777e62a0/41467_2018_6642_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/d5f870ec8689/41467_2018_6642_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/12ebcc6ad119/41467_2018_6642_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/7a8ba105042f/41467_2018_6642_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/36c5777e62a0/41467_2018_6642_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f1/6175901/d5f870ec8689/41467_2018_6642_Fig4_HTML.jpg

相似文献

1
Enhanced validation of antibodies for research applications.增强型抗体验证,适用于研究应用。
Nat Commun. 2018 Oct 8;9(1):4130. doi: 10.1038/s41467-018-06642-y.
2
Antibody validation by Western blotting.通过蛋白质免疫印迹法进行抗体验证。
Methods Mol Biol. 2012;823:139-55. doi: 10.1007/978-1-60327-216-2_10.
3
A high-throughput pipeline for validation of antibodies.高通量抗体验证管道。
Nat Methods. 2018 Nov;15(11):909-912. doi: 10.1038/s41592-018-0179-8. Epub 2018 Oct 30.
4
Antibody validation for Western blot: By the user, for the user.免疫印迹法抗体验证:用户主导,用户受益。
J Biol Chem. 2020 Jan 24;295(4):926-939. doi: 10.1074/jbc.RA119.010472. Epub 2019 Dec 9.
5
Antibodies That Work Again and Again and Again.反复发挥作用的抗体。
Methods Mol Biol. 2017;1554:41-59. doi: 10.1007/978-1-4939-6759-9_2.
6
Recommendations for description and validation of antibodies for research use.用于研究的抗体的描述和验证建议。
J Steroid Biochem Mol Biol. 2016 Feb;156:40-2. doi: 10.1016/j.jsbmb.2015.11.021. Epub 2015 Dec 2.
7
Antibody Validation Strategy for Nuclear Receptors.核受体的抗体验证策略
Methods Mol Biol. 2019;1966:79-99. doi: 10.1007/978-1-4939-9195-2_7.
8
When antibodies mislead: the quest for validation.当抗体产生误导时:寻求验证
Nature. 2020 Sep;585(7824):313-314. doi: 10.1038/d41586-020-02549-1.
9
Antibodypedia, a portal for sharing antibody and antigen validation data.抗体百科,一个用于分享抗体和抗原验证数据的平台。
Mol Cell Proteomics. 2008 Oct;7(10):2028-37. doi: 10.1074/mcp.M800264-MCP200. Epub 2008 Jul 29.
10
Antibody validation: a view from the mountains.抗体验证:从高山上看。
N Biotechnol. 2018 Oct 25;45:1-8. doi: 10.1016/j.nbt.2018.08.002. Epub 2018 Aug 4.

引用本文的文献

1
Recent analytical advances in the detection and characterization of 3-O-sulfated heparan sulfate.3-O-硫酸化硫酸乙酰肝素检测与表征的最新分析进展
Anal Bioanal Chem. 2025 May 6. doi: 10.1007/s00216-025-05898-w.
2
Unravelling the conundrum of nucleolar NR2F1 localization using antibody-based approaches in vitro and in vivo.运用基于抗体的方法在体外和体内解析核仁中NR2F1定位的难题。
Commun Biol. 2025 Apr 10;8(1):594. doi: 10.1038/s42003-025-07985-1.
3
Novel method of paraffin embedding cultured cells and organoids using silicone molds.

本文引用的文献

1
Response to: Should we ignore western blots when selecting antibodies for other applications?回应:在为其他应用选择抗体时,我们应该忽略蛋白质印迹法吗?
Nat Methods. 2017 Feb 28;14(3):215-216. doi: 10.1038/nmeth.4194.
2
Gene-specific correlation of RNA and protein levels in human cells and tissues.人类细胞和组织中RNA与蛋白质水平的基因特异性相关性。
Mol Syst Biol. 2016 Oct 20;12(10):883. doi: 10.15252/msb.20167144.
3
A proposal for validation of antibodies.一项抗体验证提案。
使用硅胶模具对培养细胞和类器官进行石蜡包埋的新方法。
Histochem Cell Biol. 2025 Mar 8;163(1):37. doi: 10.1007/s00418-025-02368-3.
4
Vortioxetine exhibits anti-glioblastoma activity via the PI3K-Akt signaling pathway.伏硫西汀通过PI3K-Akt信号通路展现出抗胶质母细胞瘤活性。
Iran J Basic Med Sci. 2025;28(4):401-408. doi: 10.22038/ijbms.2025.82513.17836.
5
A Primer on Proteomic Characterization of Intercellular Communication in a Virus Microenvironment.病毒微环境中细胞间通讯的蛋白质组学表征入门
Mol Cell Proteomics. 2025 Mar;24(3):100913. doi: 10.1016/j.mcpro.2025.100913. Epub 2025 Jan 23.
6
Seeing or believing in hyperplexed spatial proteomics via antibodies: New and old biases for an image-based technology.通过抗体见证或相信超复杂空间蛋白质组学:基于图像技术的新老偏差
Biol Imaging. 2024 Oct 23;4:e10. doi: 10.1017/S2633903X24000138. eCollection 2024.
7
The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β.ABCB5作为一种完整转运体ABCB5FL和一种半转运体样ABCB5β的独特性。
Cancer Drug Resist. 2024 Aug 7;7:29. doi: 10.20517/cdr.2024.56. eCollection 2024.
8
Antibody characterization is critical to enhance reproducibility in biomedical research.抗体鉴定对于提高生物医学研究的可重复性至关重要。
Elife. 2024 Aug 14;13:e100211. doi: 10.7554/eLife.100211.
9
Expression of Osteopontin and Gremlin 1 Proteins in Cardiomyocytes in Ischemic Heart Failure.骨桥蛋白和 Gremlin 1 蛋白在缺血性心力衰竭心肌细胞中的表达。
Int J Mol Sci. 2024 Jul 28;25(15):8240. doi: 10.3390/ijms25158240.
10
Recommendations for Development and Validation of a Fit-For-Purpose Biomarker Assays Using Western Blotting; An-AAPS Sponsored Initiative to Harmonize Industry Practices.使用 Western Blotting 开发和验证有针对性的生物标志物检测方法的建议:AAPS 发起的旨在协调行业实践的倡议。
AAPS J. 2024 Jul 25;26(5):87. doi: 10.1208/s12248-024-00946-2.
Nat Methods. 2016 Oct;13(10):823-7. doi: 10.1038/nmeth.3995. Epub 2016 Sep 5.
4
[Letter to the Editor] The need for improved education and training in research antibody usage and validation practices.[致编辑的信] 改进研究抗体使用和验证实践方面教育与培训的必要性。
Biotechniques. 2016 Jul 1;61(1):16-8. doi: 10.2144/000114431. eCollection 2016.
5
On the Dependency of Cellular Protein Levels on mRNA Abundance.细胞蛋白质水平对mRNA丰度的依赖性
Cell. 2016 Apr 21;165(3):535-50. doi: 10.1016/j.cell.2016.03.014.
6
Near-optimal probabilistic RNA-seq quantification.近乎最优的概率 RNA-seq 定量。
Nat Biotechnol. 2016 May;34(5):525-7. doi: 10.1038/nbt.3519. Epub 2016 Apr 4.
7
The Resource Identification Initiative: A Cultural Shift in Publishing.资源识别倡议:出版领域的文化转变。
J Comp Neurol. 2016 Jan 1;524(1):8-22. doi: 10.1002/cne.23913.
8
Deep proteomic profiling of vasopressin-sensitive collecting duct cells. I. Virtual Western blots and molecular weight distributions.血管加压素敏感集合管细胞的深度蛋白质组分析。I. 虚拟蛋白质印迹和分子量分布
Am J Physiol Cell Physiol. 2015 Dec 15;309(12):C785-98. doi: 10.1152/ajpcell.00213.2015. Epub 2015 Aug 26.
9
Reproducibility crisis: Blame it on the antibodies.可重复性危机:归咎于抗体。
Nature. 2015 May 21;521(7552):274-6. doi: 10.1038/521274a.
10
Reproducibility: Standardize antibodies used in research.可重复性:规范研究中使用的抗体。
Nature. 2015 Feb 5;518(7537):27-9. doi: 10.1038/518027a.